Arnity therapeutics
Biotechnology Research • • 1-10 Employees
Company overview
| Headquarters | XX |
| Website | |
| NAICS | 541714 |
| Keywords | Asthma, LNP, Food Allergy, Mrna |
| Founded | 2025 |
| Employees | 1-10 |
Key Contact at Arnity therapeutics
Vincent Serra
CEO
Arnity therapeutics Email Formats
Arnity therapeutics uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@arnitytx.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@arnitytx.com | 100% |
About Arnity therapeutics
ARNity is advancing a proprietary mRNA immunotherapy platform with broad applicability across chronic inflammatory diseases. Our lead asset targets asthma and is backed by global IP protection through 2044. A second program is in development for food allergy, addressing another large unmet medical need. In parallel, we are building a next-generation LNP delivery platform focused on novel ionizable lipids. Several high-potential candidates with confirmed freedom-to-operate have been identified, with first patent filings scheduled for September 2025. Together, these platforms position ARNity as a differentiated player in the mRNA space, with strong IP, scalable technology, and multi-indication potential.
Arnity therapeutics revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Arnity therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Arnity therapeutics has never raised funding before.
United States
Germany
United Kingdom
Frequently asked questions
4.8
40,000 users
